Anavex Life Sciences Corp (NASDAQ:AVXL) has been given an average recommendation of “Buy” by the six analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $7.69.

A number of equities analysts have commented on AVXL shares. Janney Montgomery Scott started coverage on shares of Neurotrope in a report on Tuesday, June 18th. They issued a “buy” rating and a $14.00 price objective for the company. Roth Capital reissued a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. ValuEngine raised shares of Vistra Energy from a “hold” rating to a “buy” rating in a report on Wednesday, July 3rd. Finally, Zacks Investment Research raised shares of Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a report on Monday, July 8th.

Anavex Life Sciences stock traded down $0.28 during mid-day trading on Friday, reaching $2.54. The company’s stock had a trading volume of 1,148,712 shares, compared to its average volume of 816,102. The company has a market capitalization of $145.68 million, a price-to-earnings ratio of -6.51 and a beta of 2.38. The firm’s 50 day moving average is $3.20. Anavex Life Sciences has a twelve month low of $1.25 and a twelve month high of $4.09.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. On average, sell-side analysts forecast that Anavex Life Sciences will post -0.68 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Wedbush Securities Inc. acquired a new position in shares of Anavex Life Sciences during the first quarter valued at $43,000. Deutsche Bank AG acquired a new stake in Anavex Life Sciences in the fourth quarter worth about $28,000. Edge Wealth Management LLC lifted its holdings in Anavex Life Sciences by 200.0% in the first quarter. Edge Wealth Management LLC now owns 30,000 shares of the biotechnology company’s stock worth $91,000 after purchasing an additional 20,000 shares during the period. AllSquare Wealth Management LLC lifted its holdings in Anavex Life Sciences by 98.3% in the first quarter. AllSquare Wealth Management LLC now owns 32,390 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 16,060 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Anavex Life Sciences in the first quarter worth about $152,000. 14.27% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.

Recommended Story: Why are percentage decliners important?

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.